Processing

Please wait...

Settings

Settings

Goto Application

1. WO2014162031 - RECOMBINANT VECTORS BASED ON THE MODIFIED VACCINIA ANKARA VIRUS (MVA) AS PREVENTIVE AND THERAPEUTIC VACCINES AGAINST HEPATITIS C

Publication Number WO/2014/162031
Publication Date 09.10.2014
International Application No. PCT/ES2014/070246
International Filing Date 31.03.2014
IPC
C12N 15/863 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
863Poxviral vectors, e.g. vaccinia virus
A61K 39/29 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
29Hepatitis virus
A61P 31/14 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
CPC
A61K 2039/53
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
53DNA (RNA) vaccination
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61K 39/29
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
29Hepatitis virus
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C12N 2710/24143
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2710dsDNA Viruses
00011dsDNA Viruses
24011Poxviridae
24111Orthopoxvirus, e.g. vaccinia virus, variola
24141Use of virus, viral particle or viral elements as a vector
24143viral genome or elements thereof as genetic vector
C12N 2770/24234
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2770ssRNA Viruses positive-sense
00011ssRNA Viruses positive-sense
24011Flaviviridae
24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
24234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applicants
  • CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) [ES]/[ES]
Inventors
  • ESTEBAN RODRIGUEZ, Mariano
  • GÓMEZ RODRÍGUEZ, Carmen Elena
  • PERDIGUERO DE LA TORRE, Beatriz
Agents
  • PONS ARIÑO, Ángel
Priority Data
P 20133046702.04.2013ES
Publication Language Spanish (ES)
Filing Language Spanish (ES)
Designated States
Title
(EN) RECOMBINANT VECTORS BASED ON THE MODIFIED VACCINIA ANKARA VIRUS (MVA) AS PREVENTIVE AND THERAPEUTIC VACCINES AGAINST HEPATITIS C
(ES) VECTORES RECOMBINANTES BASADOS EN EL VIRUS MODIFICADO DE ANKARA (MVA) COMO VACUNAS PREVENTIVAS Y TERAPÉUTICAS CONTRA LA HEPATITIS C
(FR) VECTEURS RECOMBINÉS DÉRIVÉS DU VIRUS ANKARA MODIFIÉ (MVA) UTILISÉS COMME VACCINS PRÉVENTIFS ET THÉRAPEUTIQUES CONTRE L'HÉPATITE C
Abstract
(EN)
The recombinant viruses of the invention contain sequences which are inserted at the same site of insertion as that of MVA and allow the simultaneous expression of various antigens of the HCV, concretely the structural (Core, E1, E2 and p7) and non-structural (NS2, NS3, NS4A, NS4B, NS5A plus the 201 amino acids of the N-terminal region of NS5B) mature proteins. In this way, stable recombinant viruses are obtained, which allow an immune response to be triggered against a large variety of antigens of the HCV, suitable for being used as preventive and therapeutic vaccines against hepatitis C.
(ES)
Los virus recombinantes de la invención contienen secuencias que se encuentran insertadas en el mismo sitio de inserción del MVA y que permiten la expresión simultáneamente de varios antígenos del VHC, concretamente las proteínas maduras estructurales (Core, E1, E2 y p7) y no estructurales (NS2, NS3, NS4A, NS4B, NS5A más los 201 aminoácidos de la región N-terminal de NS5B). Con ello se consiguen virus recombinantes estables, que permiten el desencadenamiento de una respuesta inmune contra una gran variedad de antígenos del VHC, adecuados para ser utilizados como vacunas preventivas y terapéuticas contra la hepatitis C.
(FR)
Les virus recombinés de l'invention contiennent des séquences qui sont insérées dans le même site d'insertion du MVA et qui permettent l'expression simultanée de divers antigènes du VHC, en particulier les protéines matures structurales (Core, E1, E2 et p7) et non structurales (NS2, NS3, NS4A, NS4B, NS5A ainsi que les 201 acides aminés de la région N-terminale de NS5B). On obtient ainsi des virus recombinés stables qui permettent le déclenchement d'une réponse immunitaire contre une grande variété d'antigènes du VHC, appropriés pour être utilisés comme vaccins préventifs et thérapeutiques contre l'hépatite C.
Latest bibliographic data on file with the International Bureau